On flood protection measures for potash mines

Development of water-soluble ore deposits is associated with the necessity to preserve water blocking strata (WBS), which separate aquifers from the mine gob. One indicator of the rate of man-induced load on WBS layers is subsidence of the earth surface, which defines the character of shift trough formation of the earth surface. The greatest threat of WBS discontinuity is posed by the areas located at the edges of a shift trough. From the perspective of Upper Kama deposit of potassium and magnesium salts, by means of mathematical modelling methods authors demonstrated that in the capacity of threat indicators of WBS hole destruction it is possible to use the following parameters of a shift trough: edge length scaled to the depth of mining operations and maximum  subsidence of the earth surface. Critical combination of these factors is responsible for the discontinuity at the edges of water blocking strata. These parameters of a shift trough can easily be controlled by instrumental procedures and can be included in the basics of a general monitoring system of WBS state at potash mines. In order to protect the mine from the inrush of fresh water, it is necessary to form softening zones at the edges of mined-out areas near permanent or temporary borders of mining operations. Authors review different options of softening zone formation. Numerical tests have demonstrated that the most efficient way to protect water blocking strata is the formation of softening zones by means of backfilling the stopes of the workable seam or its exclusion from mining operations

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA

Hodgkin lymphoma (HL) represents one of the great success stories in hematology going from a uniformly fatal disease; to one that is curable in the vast majority of cases. Despite this success; approximately 5–10 % HL patients are refractory to initial treatment and 10–30 % of patients will relapse after achieving an initial complete remission. The standard treatment is second-line therapy followed by autologous hematopoietic stem cell transplantation (autoHSCT); which cures an additional 50 % of patients. Brentuximab Vedotin; “antibody-drug conjugate”; dramatically changed the possibilities of therapy for relapses/refractory HL. The article presents a review of the literature on the treatment of relapses/refractory HL